. Filoviruses are deemed biosecurity and global health risks, and as such are classified as category A priority pathogens. This 'elite' ranking is because of the high morbidity and mortality that they have caused in humans during sporadic outbreaks, because they are highly infectious and readily spread by person-to-person contact and because there is a consensus that filoviruses were weaponized during the Cold War 4 . These concerns are compounded by the fact that there are no approved vaccines or drugs to combat any filovirus infection.
Most filoviruses are endemic only in specific regions in Central Africa, although Reston ebolavirus, which has caused disease in monkeys and pigs but not humans, is endemic in the Philippines 5 . Moreover, a new filovirus, representing a tentative third genus, was recently discovered in Spain 6 . However, there have been instances of unintentional importation; for example, importation of Marburg virus from infected monkeys from Uganda sparked an outbreak with human fatalities in Europe in 1967 and, similarly, importation of infected monkeys from the Philippines caused widespread disease and death in monkeys housed in a facility in Reston, Virginia, USA. Hence, there is a pressing need to develop treatments for filovirus infections, whether they arise at endemic sites or are caused by accidental or intentional means (for example, through importation or by bioterrorists, respectively).
The first step of any virus life cycle (FIG. 1 ) is binding to the host cell surface. In the case of filoviruses, the first cells infected are macrophages and dendritic cells, but these viruses can infect most cell types (with the notable exceptions of lymphocytes and other non-adherent cells 7 ). All viruses use attachment factors and/or entry receptors to bind to host cells. Although an attachment factor serves only as a binding moiety, an entry receptor is currently defined as a molecule on the cell surface that actively promotes viral internalization or actively induces penetration 8 (the process by which the virus breaches a cell membrane barrier and thereby releases its genome into the cytoplasm). Filoviruses have been shown to engage host cell attachment factors, such as DC-SIGN (dendritic cell-specific ICAM3-grabbing non-integrin; also known as CD209) and L-SIGN (liver and lymph node SIGN; also known as CLEC4M) [9] [10] [11] [12] . However, which molecules serve as entry receptors remains unclear 7, [13] [14] [15] . Several cell surface proteins such as integrins and tyrosine protein kinase receptor 3 (TYRO3) family members enhance filovirus entry 16, 17 but do not function as physical virus receptors 18, 19 . Recent evidence indicates that T cell immuno globulin and mucin domain-containing 1 (TIM1; also known as HAVCR1) serves as a filovirus receptor on epithelial cells 14 , but how it promotes entry and which molecules serve as entry receptors on the surface of non-epithelial cells remain to be determined.
Following binding to the cell surface, filoviruses are internalized by a macropinocytosislike process [20] [21] [22] and trafficked to a late endocytic compartment. Because they are surrounded by a membrane, filoviruses penetrate into the cytoplasm by membrane fusion with the limiting membrane of the late endosome. After entry, the viral genome is replicated and transcribed, new viral proteins are synthesized, and new virions assemble and bud from the cell surface 23, 24 (FIG. 1) .
Given its place at the starting line of infection, the entry process is an ideal target for antiviral intervention: beat the virus before it gets into the cell. Recent successes in developing antivirals and antibodies that target entry by viral pathogens, including HIV and influenza virus, have been guided by detailed knowledge of the viral entry mechanisms 25, 26 . Therefore, it is imperative to learn as much as possible about how filoviruses enter cells.
In this Progress article, we discuss recent insights into filovirus entry, focusing on the viral penetration event. We describe the role of the EBOV glycoprotein (GP) and possible roles of a newly identified host entry factor [27] [28] [29] , Niemann-Pick C1 (NPC1), in this entry process.
EBOV GP mediates viral entry
All stages of EBOV entry (binding to and internalization from the cell surface, as well as trafficking to and fusion with the limiting membrane of a late endosome) are mediated by trimeric GP spikes 15, 30 arrayed around the EBOV particles (FIG. 1) . After delivering the virus to a late endosomal compartment, GP must be primed and then triggered to induce the crucial membrane fusion event that leads to viral penetration and ensuing replication. Priming EBOV GP to a fusion-competent state. On the basis of structural information, EBOV GP is categorized as a class I viral fusion protein and, like all fusion proteins in its class, it must be proteolytically primed to set it in a state that is capable of responding to a fusion trigger
. Most class I viral fusion proteins are primed either in the Golgi compartment during their biosynthesis or in the extracellular environment following the release of newly budded virus particles from the surface of an infected cell. For most class I viral fusion proteins, priming involves the removal of only a few, if any, amino acids 31, 32 . EBOV GP is synthesized as a single polypeptide chain that is cleaved in the Golgi (during biosynthesis) by a furin-like protease into its receptor-binding (GP1) and fusion (GP2) subunits, which remain together through non-covalent interactions and through a disulphide bond. Three GP1-S-S-GP2 units come together to form the homotrimer that protrudes from the virion surface 15, 30 . However, in contrast to similarly organized class I viral fusion proteins (for example, influenza virus haemagglutinin), the cleavage site that separates GP1 and GP2 is dispensable for entry 33 as well as for infection and pathogenesis 34 . Therefore, the simple furin cleavage event is not sufficient to prime GP.
Full priming occurs only on fully formed EBOV particles and only after they have been bound, internalized and trafficked to a late endosome in a new target cell (FIG. 1) . There, functional priming is mediated by the cysteine proteases cathepsin B and cathepsin L 35, 36 , which cleave GP1 within the β13-β14 loop 13, 30, 37 , a segment that probably crosses over the fusion loop in the native trimer 38 . Cathepsin priming removes ~60% of the amino acids from GP1, including the mucin-like domain, the glycan cap, and the outermost β-strand of the proposed receptor-binding region (RBR; within the receptor-binding subunit) 13, 15, 30, [39] [40] [41] [42] ( FIG. 2a,b) . Priming seems to occur in two steps, with cathepsin L cleaving GP1 to a 20 kDa species, which is cleaved further by cathepsin B to 19 kDa 13, 36, 37 (FIG. 2a) . 20 kDa and 19 kDa GP (that is, GP containing 20 kDa and 19 kDa GP1, respectively) have different biochemical and biological properties. Entry of pseudovirions bearing 20 kDa GP is strongly inhibited by cathepsin B antagonists, whereas entry of pseudovirions bearing 19 kDa GP is not 36, 43 . Moreover, 19 kDa GP is more sensitive to proteolysis 43 and more readily triggered to undergo a conformational change 44 than 20 kDa GP. Two hypotheses have been proposed to explain why GP undergoes such a marked proteolytic priming event. It could be that this priming exposes the RBR of GP so that it can interact with an endosomal receptor 45 . Alternatively, or in addition, priming may potentiate GP for fusion triggering 36, 43 . As discussed below, both possibilities have been supported by experimental evidence 28, 29, 44 . Triggering EBOV GP. After priming, all viral fusion proteins must be stimulated by a fusion trigger
, of which there are four Figure 1 | The life cycle of EBOV. Ebola virus (EBOV) binds to attachment factors and receptors on the cell surface through the viral spike protein, glycoprotein (GP) (step 1). The virus is then internalized into a macropinosome (step 2) and trafficked to an endosomal compartment containing the cysteine proteases cathepsin B (CatB) and CatL (step 3). These proteases digest GP to a 19 kDa form, which is then triggered to initiate fusion between the viral and endosomal membranes (step 4). After fusion, the viral nucleocapsid is released into the cytoplasm, where the genome is replicated (step 5) and transcribed (step 6) with the aid of the viral proteins VP35, VP30 and L, and viral mRNAs are then translated (step 7). mRNAs encoding GP are brought to the endoplasmic reticulum (ER) (step 8), where GP is synthesized, modified with N-linked sugars and trimerized. GP is further modified in the Golgi and delivered to the plasma membrane in secretory vesicles (step 9). At the plasma membrane the ribonucleoprotein complex (RNA plus nucleoprotein (NP)) and associated viral proteins assemble with the membrane-associated proteins (matrix proteins VP24 and VP40, and GP), and the resultant virions bud from the cell surface (step 10). Non-structural forms of GP, including soluble GP (sGP), are also secreted (step 11). Nature Reviews | Microbiology known types: interaction of the receptorbinding subunit of the fusion protein (or a companion viral attachment protein) with a cell surface receptor; sequential interactions (on the cell surface) with a receptor and co-receptor; exposure to low pH in endosomes; and sequential interaction with a cell surface receptor followed by exposure to low pH in endosomes 31 . Therefore, all known receptor-triggered fusion events occur at the cell surface, whereas all low pH-triggered events occur in endosomes.
Stimulation by the relevant fusion trigger (for example, receptor binding and/or low pH) elicits a series of marked conformational changes
. A key early effect is exposure of a hydrophobic fusion loop (or fusion peptide), a protein segment that is vital for fusion and is either buried or tacked down in the native fusion protein.
When this fusion loop is liberated and repositioned, it binds to the target membrane, forming a rod-shaped intermediate (a prehairpin), which bridges the viral and target membranes. Next, the fusion protein bends approximately in half, and in so doing pulls the viral membrane and the target membrane (either cell surface or endosome) into close proximity, ultimately leading the two membranes to merge 31, 32 . The manner by which primed EBOV GP is triggered does not conform to any known triggering mechanism. A low pH is needed 36 (FIG. 2a) to facilitate conformational changes in primed GP 44, 46 , as is the case for the functionally homologous protein in some other viruses; however, it is not sufficient to trigger primed GP, and apparently nor are changes in cation concentrations or further cathepsin digestion 43, 44 . In vitro, mild treatment (preferentially at low pH) with a reagent that reduces disulphide bonds can trigger primed GP to bind target membranes through its fusion loop 44 . Although these observations support the hypothesis that extensive processing potentiates GP for triggering, how primed GP is triggered in vivo and why triggering of primed GP remains sensitive to the cysteine protease inhibitor E64 (REFS 36, 43) remain unsolved mysteries.
NPC1 is a key EBOV entry factor
Aside from the general endocytic machinery and cathepsins, it has remained unclear which host cell factors are crucial for EBOV entry. However, two recent studies have identified new players in the process. Intriguingly, both studies reveal a key role for the endosomal membrane protein NPC1
(REFS 27,28).
NPC1 is required for EBOV entry. Carette et al. 27 identified NPC1 as a crucial EBOV entry factor through a human genomewide haploid genetic screen 27 , an approach that had previously unearthed genes (and their encoded proteins) that are required for bacterial intoxication and influenza virus infection 47 . Of the genes identified, Green spheres depict Lys114, Lys115 and Lys140 in the receptor-binding region (RBR); mutations at these residues impair binding of primed GP to Niemann-Pick C1 (NPC1) and GP-mediated infection. c | Possible roles for NPC1 in triggering EBOV fusion. Following delivery of the virus to a late endosome-lysosome and GP priming by cathepsins, the primed GP binds the C loop of NPC1. In the first model, NPC1 is the additional factor (see part a) that, together with low endosomal pH, triggers the conformational changes which liberate and relocate the fusion loop, leading to membrane fusion and, therefore, penetration of the genome into the cytoplasm to initiate replication. In the second model, NPC1 binding to primed GP is necessary, but not sufficient, to trigger GP, and one or more additional factors are required. In the third scenario, NPC1 binds primed GP, linking the virus to the endosomal membrane, but does not induce conformational changes in GP; in this case, an additional factor triggers fusion. If the third model is correct, NPC1 must have important roles just upstream of fusion triggering; it may also have an additional upstream role (or roles) if either of the first two models applies. Part a of the figure is modified, with permission, from all those encoding proteins with known functions have roles in the maturation or function of late endosomes or lysosomes. These include cathepsin B, a previously described EBOV entry factor 35, 36 (FIG. 2a) , and all six subunits of the HOPS complex, a multisubunit machine that assembles the components required for fusion between late endocytic organelles (for example, between late endosomes and lysosomes, to form endolysosomes) [48] [49] [50] . The gene with the greatest number of hits encodes NPC1, a ubiquitously expressed multimembranespanning protein that resides primarily in the limiting membranes of late endosomes and lysosomes 51, 52 . The best recognized role of NPC1 is to aid cholesterol egress out of late endosomes for redistribution to cellular membranes, including the endoplasmic reticulum and plasma membranes. Consequently, when cells are deficient in NPC1, cholesterol accumulates in late endosomes-lysosomes [52] [53] [54] . Taking a different approach, Cote et al. 28 screened a chemical library for compounds that inhibit infection by pseudovirions bearing EBOV GP 28 . They showed that inhibitory compound 3.0 and its more potent derivative, compound 3.47, induce cholesterol accumulation in endosomes, a hallmark of Niemann-Pick disease type C (NPC; caused by mutations in the genes encoding NPC1 or NPC2). In a follow-up experiment that tested five proteins involved in cholesterol homeostasis, NPC1 was the only one to emerge as essential for EBOV entry.
Importantly, both groups found that the role of NPC1 in EBOV entry is independent of its function in cholesterol egress: cells lacking NPC2, an NPC1 partner for cholesterol egress 52, 55 , or expressing a mutant NPC1 defective in cholesterol egress are still susceptible to EBOV GP-mediated infection.
What is the role of NPC1 in EBOV entry?
NPC1 is clearly involved in EBOV entry, and several lines of evidence suggest that it functions close to, or at the step of, viral membrane-endosomal membrane fusion. First, NPC1 is primarily located in late endosomes-lysosomes, the compartments through which EBOV is thought to enter the cytoplasm. Second, EBOV GP particles accumulate in late endosomes and fail to access the cytoplasm in NPC1-null cells. Third, particles bearing primed EBOV GP also require NPC1, suggesting that NPC1 functions after cathepsin-mediated priming 27, 28 (FIG. 1) .
But what is the precise role of NPC1? Cote et al. 28 showed that a primed trimeric GP ectodomain (GPʹ-Ecto) binds to a preparation of late endosomes-lysosomes from cells expressing exogenous NPC1, but not to a similar preparation from NPC1-null cells. When NPC1-containing late endosome-lysosome membranes with bound GPʹ-Ecto are subsequently solubilized with a detergent, GPʹ-Ecto can be immunoprecipitated by an antibody specific for NPC1. Cote et al. further observed a correlation between the potency of compound 3.0 (and two of its derivatives) and its ability to block EBOV entry and GPʹ-Ecto binding to NPC1-containing late endosome-lysosome membranes. They therefore proposed that NPC1 binds to primed GP. Miller et al. 29 have recently provided strong support for this idea. They demonstrated a direct interaction between primed GP and the second lumenal loop -the C loop -of NPC1 that depends on previously identified critical residues within the RBR in GP1 (REFS 13, (39) (40) (41) (42) . Hence, appealingly, cathepsin priming renders the RBR accessible for binding to NPC1 (FIG. 2b) .
Cote et al. 28 and Miller et al. 29 further proposed that, following binding, NPC1 participates in triggering the fusion activity of primed GP. In the simplest model (model 1 ,  FIG. 2c) , at low pH NPC1 is the additional factor that is both necessary and sufficient for triggering GP (FIG. 2a) to undergo the requisite fusion-inducing conformational changes
. An alternative possibility  (model 2, FIG. 2c) is that NPC1 participates in, but is not solely responsible for, fusion triggering at low pH. If either of these models is correct, triggering of EBOV fusion would represent an important exception to the general rule that receptor-mediated triggering of viral fusion proteins occurs
Box 1 | Pathway of viral membrane fusion
All enveloped viruses penetrate into host cells using a viral membrane fusion protein. Class I fusion proteins are trimers of three identical units (see the figure; the initial and final protein depictions are based on X-ray structures of several class I fusion proteins). For most of these proteins, including Ebola virus (EBOV) glycoprotein, influenza virus haemagglutinin and retroviral Env proteins, each monomeric unit consists of a receptor-binding (rb) and a fusion (f) subunit, which are initially present in a single polypeptide chain. Priming by proteolytic cleavage (generally between the receptor-binding and fusion subunits) converts the protein from a fusion-incompetent to a fusion-competent (metastable) form that can respond to a fusion trigger. Triggering exposes and repositions the previously hidden (or tacked-down) fusion loop (or fusion peptide), which then binds hydrophobically to the target membrane. The structure that bridges the viral and target membranes is envisioned to be a trimeric coiled-coil rod, termed a prehairpin, composed of the three identical fusion subunits. Subsequent fold-back steps drive the protein through prebundle, bundle and trimer-of-hairpins configurations; the trimer-of-hairpins configuration contains a six-helix bundle (6HB) in the case of class I fusion proteins. These structural changes drive the viral (see the figure; blue) and target (see the figure; pink) membranes through stages of close apposition and hemifusion, followed by formation of a fusion pore that eventually grows large enough for the viral genome to pass through. Movement of or changes in the receptor-binding subunit are needed to unclamp the fusion subunit, converting it from the fusion-incompetent to the fusion-competent state. Class II and class III fusion proteins undergo similar conformational changes (forming prehairpins and trimers-of-hairpins) and induce fusion through similar stages of membrane dynamics. only at the cell surface 31 . In a third model (model 3, FIG. 2c) , NPC1 binds to GP1 but does not actively participate in triggering, which must be mediated by an unknown additional factor, perhaps the reducing potential in endosomes 44 . If model 3 is correct, then NPC1 probably has essential roles close to, but upstream of, fusion triggering (see below).
Irrespective of whether NPC1 actively participates in fusion triggering, there are additional ways in which it might support fusion after cathepsin priming. First, binding of NPC1 to primed GP would attach EBOV to the limiting membrane of the late endosomelysosome 51, 52 , ensuring that the viral genome is delivered directly into the cytoplasm (instead of into small vesicles found within the late endosome-lysosome 49 ). Second, by binding to primed GP, NPC1 may protect it from further inactivating proteolysis 43, 44 . Finally, NPC1 may affect the composition of late endosomes-lysosomes 52 (the lumen and/ or limiting membrane), generating conditions that are optimal for fusion.
NPC1 as an antiviral target
These studies have raised hopes for the development of a therapeutic agent that targets NPC1 to treat infections by EBOV and potentially other filoviruses. Indeed, compounds that potently inhibit EBOV entry block binding of primed GP to NPC1-containing late endosome-lysosome membranes 28 . Furthermore, mice that are heterozygous for the gene encoding NPC1 -the late endosomes-lysosomes of which should possess less NPC1 than those of normal mice -are significantly protected from challenges with EBOV and Marburg virus 27 . Moreover, NPC1 is required for entry of all five species of ebolavirus as well as Marburg virus 27, 28 . Curiously, given its central role in endosome function and dynamics 49, 52, 54 , NPC1 does not seem to be required for the entry of ten other viruses tested, including several that enter though late endosomes 56 . Hence, the collective findings of recent studies [27] [28] [29] suggest that by targeting NPC1 it may be possible to prevent entry and infection by multiple filoviruses, without having dire cell biological consequences.
Another set of observations have implications for inhibitor design. U18666A is a small molecule that has been used extensively to mimic the phenotype of cells from patients with NPC 53, 57 ; for example, U18666A causes cholesterol accumulation in late endosomes, similarly to compounds 3.0 and 3.47. Moreover, U18666A blocks EBOV GP-mediated entry and infection 27 (J. Shoemaker, C. Scully, G. Olinger and J.M.W., unpublished observations). Curiously, although U18666A has been shown to interact with purified NPC1 (REF. 58 ), it does not block binding of primed EBOV GP to late endosome-lysosome membranes 28 . This suggests that there are two classes of NPC1-interacting agents that can impede filovirus entry and infection. One class, typified by compound 3.47, may bind to the site on NPC1 that engages primed GP, to competitively block GP binding to the membrane. Another class, typified by U18666A, may bind to a different site on NPC1, disabling its function in maintaining the proper composition of late endosomeslysosomes 52, 57 . Because there may be other late endosome-lysosome constituents, in addition to NPC1, that are needed for EBOV entry (models 2 and 3, FIG. 2c) , the second class of compound might prevent EBOV entry without physically precluding the NPC1-GP interaction. Despite the considerations raised above, it may of course be challenging to use either class of compound in a therapeutic setting, given the importance of NPC1 to endosome function and cholesterol homeostasis [51] [52] [53] [54] 57, 59, 60 .
Perspectives
The recent studies by Carette et al. 27 , Cote et al. 28 and Miller et al. 29 have offered us fresh insights into the cell biology of filovirus entry and have identified a new host protein, NPC1, that may serve as a therapeutic target. However, many questions remain unanswered, and there are several avenues of investigation to be followed.
First and foremost, further biochemical and cell biological studies are needed to determine the exact roles of NPC1 in EBOV entry. Which residues of the NPC1 C loop and primed GP engage each other? What is the affinity of the interaction? Is the interaction sufficient to trigger fusion at low pH (model 1 , FIG. 2c) ? If additional factors are required (model 2, FIG. 2c) , what are they, and do they work in concert with or sequentially to NPC1? If NPC1 is not actively involved in triggering fusion (model 3, FIG. 2c) , which of several possible alternative parts does it play, and what is the bona fide fusion trigger?
It will also be important to determine whether molecules typified by compound 3.47 or U18666A can be used to treat EBOV infections in primates. Finally, structural studies should be carried out on the interface between NPC1 and primed GP to guide further development of small molecules and antibodies for the prevention or treatment of filovirus infections.
